Follow-up results from the SIRROUND-D trial indicate that patients with rheumatoid arthritis refractory to DMARDs who are treated with sirukumab experience sustained improvements in clinical outcomes for up to 2 years.

Sirukumab monotherapy is well tolerated and has measurable efficacy in Japanese patients with rheumatoid arthritis refractory to treatment with methotrexate or sulfasalazine, researchers report.

Patients with rheumatoid arthritis who are treated with the interleukin-6 inhibitor sirukumab experience comparable benefits to those given adalimumab, results of the phase III SIRROUND-H trial suggest.

The interleukin-6 inhibitor sirukumab could offer a therapeutic option for patients with active rheumatoid arthritis despite treatment with disease-modifying antirheumatic drugs, results of the phase III SIRROUND-D study suggest.

Sirukumab, which targets the interleukin-6 cytokine, is an effective treatment for patients with rheumatoid arthritis refractory to anti-tumor necrosis factor drugs and other biologic treatments, phase III study findings show.

There was no significant difference in treatment withdrawals between regimens containing methotrexate plus either tocilizumab 8 mg, sirukumab 100 mg, or sarilumab 200 mg, suggesting “comparable tolerability among tocilizumab, sarilumab, and sirukumab,” write Bae and Lee.